Doug Hampton

Creative Medical Technology Announces $2 Million Share Repurchase Program

by

PHOENIX, June 12, 2023 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up … Read more

Pyx Health Launches the Nation’s First Loneliness Helpline Available During National Loneliness Awareness Week

by

Company dedicated to helping people suffering from loneliness and social isolation establishes helpline to provide companionship, support and resources  TUCSON, Ariz., June 12, 2023 /PRNewswire/ — America’s loneliness epidemic has been in the spotlight recently, with the United States Surgeon General Dr. Vivek Murthy releasing a General Advisory calling attention to the public health crisis. … Read more

C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

by

MONTREAL, June 12, 2023 /PRNewswire/ – C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. “We’re pleased … Read more

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

by

SIERRA results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B BLA filing for Iomab-B expected by year end 2023 based on positive pivotal Phase 3 SIERRA results NEW YORK, June 12, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive … Read more

The 20th CACLP & 3rd CISCE Closed with Record-breaking Numbers in Nanchang

by

NANCHANG, China, June 12, 2023 /PRNewswire/ — From 28 to 30 May 2023, the 20th China Association of Clinical Laboratory Practice Expo (CACLP) and the 3rd China IVD Supply Chain Expo (CISCE), recognized as the world’s leading in vitro diagnostics (IVD) exhibition, were successfully closed in Nanchang, China. With an exhibition space of 130,000 sqm, the … Read more

Finturf Empowers Chiropractors to Approve 100% of Patient Financing Applications

by

GLENDALE, Calif., June 12, 2023 /PRNewswire/ — Finturf is proud to announce its partnerships with a diverse range of financing providers catering to the chiropractic and neuropathic industries. Financing options offered through our new program include: Chiropractors treat more patients using Finturf’s 100% approval programs and up to $25k credit lines. Tweet this Lines of credit … Read more

MarketsandMarkets™ Expands its Senior Leadership Team and Service Offerings with Strategic Appointments in its Healthcare Vertical

by

CHICAGO, June 12, 2023 /PRNewswire/ — MarketsandMarkets™ is pleased to announce the appointment of Siddharth Saha as the Senior Vice President – Healthcare. In his current role, Siddharth will play a crucial role in strengthening MarketsandMarkets’ position in the healthcare research and consulting landscape. His extensive experience will be instrumental in driving the growth and success … Read more

une étude révèle des résultats prometteurs en matière d’immunothérapie dans le traitement du cancer de la peau

by

HAMBOURG, Allemagne, 12 juin 2023 /PRNewswire/ — Une étude révolutionnaire a été présentée le 10 juin lors du congrès hybride organisé à Hambourg par l’Académie européenne d’allergologie et d’immunologie clinique (EAACI). Cette étude, menée par des chercheurs du King’s College de Londres et du Guy’s and St Thomas’ NHS Foundation Trust, a révélé des résultats prometteurs … Read more

EAACI:resultados prometedores para la inmunoterapia dirigida al cáncer de piel

by

Congreso anual 2023 de la Academia Europea de Alergia e Inmunología Clínica: un estudio muestra resultados prometedores para la inmunoterapia dirigida al cáncer de piel HAMBURGO, Alemania, 12 de junio de 2023 /PRNewswire/ — El 10 de junio se presentó un estudio innovador en el Congreso Híbrido en Hamburgo organizado por la Academia Europea de Alergia … Read more

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

by

Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancers Observed partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor type Clinical strategy focused on IDE397 combinations, including with AMG … Read more